Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Suma Krishnan also recently made the following trade(s):

• On Friday, December 13th, Suma Krishnan sold 25,000 shares of Krystal Biotech stock. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00.

Krystal Biotech Trading Up 4.2 %

Shares of Krystal Biotech stock traded up $7.51 during trading on Monday, reaching $186.89. The stock had a trading volume of 299,929 shares, compared to its average volume of 284,811. The company has a market capitalization of $5.38 billion, a price-to-earnings ratio of 62.51 and a beta of 0.87. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The stock has a fifty day moving average price of $163.50 and a two-hundred day moving average price of $173.69.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech's quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 earnings per share. On average, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Remove Ads

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Citigroup lifted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $220.00.

Institutional Trading of Krystal Biotech

A number of hedge funds have recently made changes to their positions in KRYS. Norges Bank bought a new position in Krystal Biotech in the 4th quarter valued at about $34,391,000. Soleus Capital Management L.P. boosted its stake in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after purchasing an additional 141,400 shares during the period. Segall Bryant & Hamill LLC grew its holdings in Krystal Biotech by 352.4% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company's stock valued at $28,605,000 after buying an additional 122,407 shares in the last quarter. State Street Corp increased its position in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock worth $264,455,000 after buying an additional 119,936 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Krystal Biotech during the fourth quarter worth $15,989,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).